Elicio is engineering
potent immuno-therapies for an array of aggressive cancers
Elicio, based in Cambridge Ma, is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to defeat cancer. By combining expertise in materials science and immunology, Elicio is engineering potent Amphiphile immunotherapies including lymph node targeted cell therapy activators, immunomodulators, and vaccines for an array of aggressive cancers. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed by Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, in the Koch Institute of Cancer Research at the Massachusetts Institute of Technology. Elicio’s lead Amphiphile vaccine targeting pancreatic cancer and colorectal cancer will begin initial patient studies in 2020.